R01HG013986
Project Grant
Overview
Grant Description
ADVANCING RARE DISEASE DISCOVERY THROUGH TECHNOLOGICAL AND METHODOLOGICAL APPROACHES USING AN INTUITIVE PLATFORM, SEQR - PROJECT SUMMARY / ABSTRACT OVER HALF OF ALL RARE DISEASE FAMILIES REMAIN UNDIAGNOSED FOLLOWING EXOME AND GENOME SEQUENCING ANALYSIS. REMARKABLE DEVELOPMENTS IN GENOMIC TECHNOLOGIES, ANALYTICAL TOOLS, AND INNOVATIVE DATA SHARING ARE ADVANCING MENDELIAN GENE DISCOVERY. HOWEVER, THE BENEFITS OF THESE NOVEL ADVANCES WILL ONLY BECOME REALIZED IF THEY ARE INTEGRATED INTO WIDELY ACCESSIBLE PLATFORMS FOR GENOMIC ANALYSIS. THE BROAD INSTITUTE CENTER FOR MENDELIAN GENOMICS HAS SUPPORTED THE DEPLOYMENT AND ONGOING DEVELOPMENT OF THE SEQR GENOMIC ANALYSIS PLATFORM, WHICH IS FREELY AVAILABLE TO THE COMMUNITY EITHER ON THE ANVIL PLATFORM OR AS AN OPEN-SOURCE TOOL THAT CAN BE INSTALLED LOCALLY. THIS PROPOSAL SEEKS TO ADVANCE THE DISCOVERY RATE FOR RARE DISEASE THROUGH ONGOING DEVELOPMENT OF THE SEQR PLATFORM, INCORPORATING AND EVALUATING THE IMPACT OF THREE NOVEL ADVANCES: 1) INNOVATIVE DATA SHARING THROUGH VARIANT LEVEL MATCHING BY CONNECTING SEQR TO A GROWING FEDERATED PLATFORM OF RARE DISEASE AND POPULATION GENOMIC DATA WITH ASSOCIATED PHENOTYPE; 2) DEPLOYMENT OF AUTOMATED ANALYTICAL TOOLS ON PREVIOUSLY EXAMINED AND UNSOLVED CASES TO IDENTIFY VARIATION THAT IS NEWLY IMPLICATED AS PATHOGENIC IN GENES WITH KNOWN DISEASE ASSOCIATIONS OR IN GENES THAT ARE NEWLY IMPLICATED IN DISEASE; AND 3) INCORPORATION OF NOVEL TECHNOLOGIES SUCH AS LONG READ DNA AND RNA SEQUENCING DATA THAT CAN BE EASILY ANALYZED IN A GENOME-WIDE MANNER. WE WILL STUDY THE IMPACT OF THESE NOVEL ADVANCES BY ANALYZING THE DIAGNOSTIC YIELD OF EACH APPROACH. AS SEQR IS FREELY AVAILABLE AND OPEN SOURCE, OUR PROPOSAL DEMOCRATIZES THE PROCESS OF GENETIC DISCOVERY, EMPOWERING RESEARCHERS AND CLINICIANS TO RESOLVE DIAGNOSTIC VARIANTS, AND ACCELERATE THE RATE OF DIAGNOSIS FOR THE GLOBAL POPULATION OF INDIVIDUALS WITH RARE GENETIC DISEASE.
Awardee
Funding Goals
NHGRI SUPPORTS THE DEVELOPMENT OF RESOURCES AND TECHNOLOGIES THAT WILL ACCELERATE GENOME RESEARCH AND ITS APPLICATION TO HUMAN HEALTH AND GENOMIC MEDICINE. A CRITICAL PART OF THE NHGRI MISSION CONTINUES TO BE THE STUDY OF THE ETHICAL, LEGAL AND SOCIAL IMPLICATIONS (ELSI) OF GENOME RESEARCH. NHGRI ALSO SUPPORTS THE TRAINING AND CAREER DEVELOPMENT OF INVESTIGATORS AND THE DISSEMINATION OF GENOME INFORMATION TO THE PUBLIC AND TO HEALTH PROFESSIONALS. THE SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM IS USED TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM IS USED TO FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Massachusetts
United States
Geographic Scope
State-Wide
Related Opportunity
The Broad Institute was awarded
SEQR Platform: Advancing Rare Disease Discovery with Innovative Technologies
Project Grant R01HG013986
worth $3,349,527
from National Human Genome Research Institute in September 2025 with work to be completed primarily in Massachusetts United States.
The grant
has a duration of 3 years 9 months and
was awarded through assistance program 93.172 Human Genome Research.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
9/8/25
Start Date
6/30/29
End Date
Funding Split
$3.3M
Federal Obligation
$0.0
Non-Federal Obligation
$3.3M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
R01HG013986
SAI Number
R01HG013986-3869297906
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75N400 NIH National Human Genome Research Institute
Funding Office
75N400 NIH National Human Genome Research Institute
Awardee UEI
H5G9NWEFHXN4
Awardee CAGE
5BP51
Performance District
MA-90
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Modified: 9/24/25